Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
6.00% $2.65
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 108.10 mill |
EPS: | -1.380 |
P/E: | -1.920 |
Earnings Date: | May 08, 2024 |
SharesOutstanding: | 40.79 mill |
Avg Daily Volume: | 0.0132 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -1.920 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -1.920 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 2.40 - 2.90 ( +/- 9.51%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-08-16 | Grossman Paul David | Buy | 4 386 | Common Stock |
2022-08-15 | Grossman Paul David | Buy | 4 826 | Common Stock |
2023-08-31 | Mcnamara Robert | Sell | 12 292 | Non-Qualified Stock Option (right to buy) |
2023-06-02 | Mcnamara Robert | Buy | 18 815 | Common Stock |
2023-08-31 | Mcnamara Robert | Sell | 18 815 | Common Stock |
INSIDER POWER |
---|
97.71 |
Last 82 transactions |
Buy: 28 174 863 | Sell: 2 326 861 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $2.65 (6.00% ) |
Volume | 0.0155 mill |
Avg. Vol. | 0.0132 mill |
% of Avg. Vol | 117.15 % |
Signal 1: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.